MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
25.43
+0.34
+1.36%
Pre Market: 25.47 +0.04 +0.16% 06:37 07/22 EDT
OPEN
25.20
PREV CLOSE
25.09
HIGH
25.57
LOW
25.07
VOLUME
562
TURNOVER
0
52 WEEK HIGH
28.35
52 WEEK LOW
19.69
MARKET CAP
4.35B
P/E (TTM)
11.62
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD)
TipRanks · 14h ago
Tracking Baker Brothers Portfolio: Q1 2026 Update
Seeking Alpha · 17h ago
Mizuho Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
TipRanks · 18h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 18h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 18h ago
ACADIA Pharmaceuticals Is Maintained at Outperform by BMO Capital
Dow Jones · 22h ago
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
Benzinga · 22h ago
Acadia Pharmaceuticals price target raised to $36 from $34 at BMO Capital
TipRanks · 22h ago
More
About ACAD
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.